Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double Blind, Placebo Controlled, Parallel Group, Multi-Center Study With a Double Blind Extension Investigating the Efficacy and Safety of a Fast- Dissolving ("Melt") Formulation of Desmopressin for the Treatment of Nocturia in Adults

Next Previous
Trial Profile

A Randomized, Double Blind, Placebo Controlled, Parallel Group, Multi-Center Study With a Double Blind Extension Investigating the Efficacy and Safety of a Fast- Dissolving ("Melt") Formulation of Desmopressin for the Treatment of Nocturia in Adults

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 14 Jan 2020

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Desmopressin (Primary)
  • Indications Nocturia
  • Focus Registrational; Therapeutic Use
  • Sponsors Ferring Pharmaceuticals

Most Recent Events

  • 21 Jun 2018 According to a Ferring Pharmaceuticals media release, the U.S. FDA granted Ferring Pharmaceuticals Inc. approval to market NOCDURNA, the first sublingual tablet for the treatment of nocturia due to nocturnal polyuria in adults who awaken at least two times per night to void. The FDA approval of NOCDURNA is based on three double-blind trials (NCT01223937, NCT01262456 and NCT00477490) and one open-label extension trial (NCT00615836, up to three years).
  • 05 Feb 2015 Based on the results of this trial, sublingual desmopressin [Nocdurna] orally disintegrating tablets were approved in Canada for the treatment of nocturia in adults, according to a Ferring Canada media release.
  • 06 Jun 2012 New source identified and integrated (ClinicalTrials.gov: US National Institutes of Health; Parent trial: NCT00477490).

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top